Trial Profile
Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Early breast cancer; Male breast cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms BioKey
- 17 Apr 2020 Status changed from recruiting to completed.
- 15 Jul 2019 Protocol has been amednded with the addition of 2 more treatment arms and planned number of patients also increasing from 34 to 54
- 15 Jul 2019 Planned number of patients changed from 34 to 54.